India's Decade of Collaboration
Harvard Business Review
MAY 31, 2011
Biocon also sources drug molecules from other partners, especially from developing countries, such as the Cuba-based Center of Molecular Immunology (CMI). In this fluid system, Biocon finances CMI's inventive R&D, while using the funds from the Pfizer deal to finance its own R&D and go-to-market activities.
12 
Let's personalize your content